구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Abraxane |
Overview Company | Boston Scientific Corporation |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | target engagement and suppression of TGFβ signaling |
MoA Biomarker | Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (24 |
Clinical Safety signal | thrombocytopenia (24 |
Clinical Selected reported efficacy | ORR 41.8% |
Clinical Reported ORR | 41.8% |
Clinical Reported PFS | 7.4 |
Clinical Reported OS | 11.1 |
Clinical Result source | ClinicalTrials.gov NCT04083235 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04083235 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Abraxane |
Overview Company | Boston Scientific Corporation |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | target engagement and suppression of TGFβ signaling |
MoA Biomarker | Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia (24 |
Clinical Safety signal | thrombocytopenia (24 |
Clinical Selected reported efficacy | ORR 41.8% |
Clinical Reported ORR | 41.8% |
Clinical Reported PFS | 7.4 |
Clinical Reported OS | 11.1 |
Clinical Result source | ClinicalTrials.gov NCT04083235 |
Clinical Program phase | PHASE_1 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04083235 |
추천 비교
추천 비교